Sort
10,766 grants matching “checkpoint inhibitor”
Project 4: Combined use of immunotherapy and targeted treatments for triple negative breast cancer
$330,532Kornelia Polyak · Dana-Farber Cancer Inst · P50 · FY2021 · CA
Regulation of the ATR Checkpoint Kinase by DNA Damage
$330,426Lee Zou · Massachusetts General Hospital · R01 · FY2015 · GM
Regulation of the ATR Checkpoint Kinase by DNA Damage
$330,426Lee Zou · Massachusetts General Hospital · R01 · FY2016 · GM
Regulation of the ATR Checkpoint Kinase by DNA Damage
$330,426Lee Zou · Massachusetts General Hospital · R01 · FY2017 · GM
Regulation of the ATR Checkpoint Kinase by DNA Damage
$330,426Lee Zou · Massachusetts General Hospital · R01 · FY2018 · GM
Novel NEK2 signaling pathways in myeloma progression
$330,316Fenghuang Zhan · Univ Of Arkansas For Med Scis · R01 · FY2024 · CA
Impact of CREB-driven mechanism in shaping the tumor-immune landscape
$329,883Nagaraj S. Nagathihalli · University Of Miami School Of Medicine · R01 · FY2024 · CA
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
$329,650Leif W Ellisen · Massachusetts General Hospital · R01 · FY2007 · CA
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1
$329,650Leif W Ellisen · Massachusetts General Hospital · R01 · FY2008 · CA
OPN neutralization monoclonal antibody 100G2 for human pancreatic cancer immunotherapy
$329,610Priscilla Simon Redd · Chemedimmune, Inc. · R43 · FY2020 · CA
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy
$329,555Ashish Ranjan · Oklahoma State University Stillwater · R37 · FY2021 · CA
Developing novel combination therapies for pancreatic cancer
$329,502Karina J Yoon · University Of Alabama At Birmingham · R01 · FY2019 · CA
Employing Humanized Microbiome Mice to Understand Immune Activation and Translational Therapeutic Potential in Glioblastoma
$329,317Braden Cox McFarland · University Of Alabama At Birmingham · R01 · FY2025 · CA
Employing Humanized Microbiome Mice to Understand Immune Activation and Translational Therapeutic Potential in Glioblastoma
$329,317Braden Cox McFarland · University Of Alabama At Birmingham · R01 · FY2023 · CA
The Role of pRB Family Members in Ras-mediated Tumorigenesis
$329,303Marie K Classon · Massachusetts General Hospital · R01 · FY2009 · CA
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
$329,260Shridar Ganesan · Rbhs -Cancer Institute Of New Jersey · R01 · FY2015 · CA
53BP1-Mediated Regulation of DNA Repair and Chemoresistance
$329,260Shridar Ganesan · Rbhs -Cancer Institute Of New Jersey · R01 · FY2016 · CA
Ipilimumab as an adjuvant for HIV vaccines
$329,243Mauricio De Aguiar Martins · University Of Miami School Of Medicine · K01 · FY2017 · OD
IL-15 Characterization Through Experimental Immunology
$329,175Jianhua Yu · Ohio State University · R01 · FY2017 · CA
Reprogramming the TME for immunogenic antigen-presentation
$329,175David H Munn · Augusta University · R01 · FY2023 · CA
Reprogramming the TME for immunogenic antigen-presentation
$329,175David H Munn · Augusta University · R01 · FY2021 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
$329,047Michael J Overman · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA
Novel DNA damage response gene from genomic screening
$328,974Patrick Concannon · University Of Florida · R01 · FY2016 · ES
Combining senescence-inducing and senolytic agents to improve melanoma therapy
$328,942Anna E Vilgelm · Ohio State University · R37 · FY2023 · CA
Targeting macrophages to sensitize myeloma to immune checkpoint blockade
$328,888Qing Yi · Cleveland Clinic Lerner Com-Cwru · R01 · FY2017 · CA